2022
PRECISE CURATE.AI: A prospective feasibility trial to dynamically modulate personalized chemotherapy dose with artificial intelligence.
Blasiak A, Truong A, Tan W, Kumar K, Tan S, Teo C, Tan B, Tadeo X, Tan H, Chee C, Yong W, Ho D, Sundar R. PRECISE CURATE.AI: A prospective feasibility trial to dynamically modulate personalized chemotherapy dose with artificial intelligence. Journal Of Clinical Oncology 2022, 40: 1574-1574. DOI: 10.1200/jco.2022.40.16_suppl.1574.Peer-Reviewed Original ResearchStandard-of-careSingle-agent capecitabineCapecitabine doseProspective feasibility trialClinical trialsChemotherapy doseSolid tumorsImprove patient response ratesDosing decisionsTreatment of solid tumorsIndividualize chemotherapy dosingAdvanced solid tumorsProspective clinical trialPatient response rateRandomized clinical trialsPrescribed dosePatient-specific variationsOpen-labelDosing recommendationsTumor markersOrgan dysfunctionPatient comorbiditiesDose selectionOncological indicationsCapecitabine
2021
Cryotherapy for Prevention of Taxane-Induced Peripheral Neuropathy: A Meta-Analysis
Jia J, Guo Y, Sundar R, Bandla A, Hao Z. Cryotherapy for Prevention of Taxane-Induced Peripheral Neuropathy: A Meta-Analysis. Frontiers In Oncology 2021, 11: 781812. PMID: 34912720, PMCID: PMC8667340, DOI: 10.3389/fonc.2021.781812.Peer-Reviewed Original ResearchTaxane-induced peripheral neuropathyCommon Terminology Criteria for Adverse EventsChemotherapy-induced peripheral neuropathyPeripheral neuropathyDose reductionMeta-analysisSensory neuropathyIncidence of taxane-induced peripheral neuropathyIncidence of sensory neuropathyPrevent chemotherapy-induced peripheral neuropathyLimits chemotherapy doseEfficacy of cryotherapyIncidence of motorAssociated with reduced incidenceQuality of lifeNerve conduction studiesMeta-Analysis softwareReduce patients' qualityGynecological cancer therapyNeuropathy questionnaireChemotherapy doseClinical guidelinesMotor neuropathyAdverse eventsClinical evidenceAbstract CT211: Personalized, rational, efficacy-driven chemotherapy dosing via an artificial intelligence system (PRECISE): A protocol for the PRECISE CURATE.AI pilot clinical trial
Teo C, Tan B, Tadeo X, Peng S, Soh H, Du S, Luo V, Bandla A, Sundar R, Ho D, Kee T, Blasiak A. Abstract CT211: Personalized, rational, efficacy-driven chemotherapy dosing via an artificial intelligence system (PRECISE): A protocol for the PRECISE CURATE.AI pilot clinical trial. Cancer Research 2021, 81: ct211-ct211. DOI: 10.1158/1538-7445.am2021-ct211.Peer-Reviewed Original ResearchTumor marker levelsRandomized controlled trialsChemotherapy doseSolid tumorsDrug doseDosing recommendationsMarker levelsAmerican Association for Cancer Research annual meetingsSignificant dose changesTumor marker measurementsCapecitabine-based chemotherapyMetastatic solid tumorsOptimal chemotherapy dosingRecruitment of patientsFrequent toxicitiesOpen-labelCA19-9Dose changesCohort expansionTumor markersSingle-armSuboptimal efficacyProportion of participantsChemotherapySerial measurementsPersonalised, Rational, Efficacy-Driven Cancer Drug Dosing via an Artificial Intelligence SystEm (PRECISE): A Protocol for the PRECISE CURATE.AI Pilot Clinical Trial
Tan B, Teo C, Tadeo X, Peng S, Soh H, Du S, Luo V, Bandla A, Sundar R, Ho D, Kee T, Blasiak A. Personalised, Rational, Efficacy-Driven Cancer Drug Dosing via an Artificial Intelligence SystEm (PRECISE): A Protocol for the PRECISE CURATE.AI Pilot Clinical Trial. Frontiers In Digital Health 2021, 3: 635524. PMID: 34713106, PMCID: PMC8521832, DOI: 10.3389/fdgth.2021.635524.Peer-Reviewed Original ResearchTumor marker levelsRandomised controlled trialsDrug dosePersonalised dosingSolid tumorsMarker levelsNational Healthcare GroupSignificant dose changesCapecitabine-based chemotherapyMetastatic solid tumorsDose of drugOpen-labelChemotherapy doseDose changesDosing recommendationsCohort expansionSingle-armSuboptimal efficacyProportion of participantsPrimary outcomeSecondary outcomesInterim analysisPhysician adherenceControlled trialsPrecision oncology
2019
Are we mis-estimating chemotherapy-induced peripheral neuropathy? Analysis of assessment methodologies from a prospective, multinational, longitudinal cohort study of patients receiving neurotoxic chemotherapy
Molassiotis A, Cheng H, Lopez V, Au J, Chan A, Bandla A, Leung K, Li Y, Wong K, Suen L, Chan C, Yorke J, Farrell C, Sundar R. Are we mis-estimating chemotherapy-induced peripheral neuropathy? Analysis of assessment methodologies from a prospective, multinational, longitudinal cohort study of patients receiving neurotoxic chemotherapy. BMC Cancer 2019, 19: 132. PMID: 30736741, PMCID: PMC6368751, DOI: 10.1186/s12885-019-5302-4.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsCohort StudiesDose-Response Relationship, DrugFemaleHumansLongitudinal StudiesMaleMiddle AgedNeoplasm StagingNeoplasmsPatient Reported Outcome MeasuresPeripheral Nervous System DiseasesPrevalenceProspective StudiesQuality of LifeSeverity of Illness IndexConceptsChemotherapy-induced peripheral neuropathyPeripheral neuropathyNeurotoxic chemotherapyPrevalence of sensory neuropathyCohort study of patientsCumulative chemotherapy dosePlatinum-based chemotherapyLongitudinal cohort study of patientsMeasuring chemotherapy-induced peripheral neuropathyStudy of patientsNerve conduction studiesAssessment of chemotherapy-induced peripheral neuropathyCIPN incidencePatient-reported outcome measuresAssociated with onsetLongitudinal cohort studyChemotherapy doseMotor neurotoxicityClinician-based scalesMotor neuropathySensory neuropathyChemotherapyNeuropathyNatural historyPatients